It was better than Stelara in reaching ... impacting the lives of psoriasis patients,” he added. BE VIVID will follow patients for a year after starting treatment, so additional readouts will ...

The psoriasis treatment that works for you initially ... notice better results with infliximab (Remicade) or ustekinumab (Stelara) than other biologics because the dosing of these drugs is based ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, according to a poster presented at Maui Derm Hawaii 2025. AX-158 has ...

has approved FYB202/Otulfi ®1 (ustekinumab), a biosimilar to Stelara ®2, for the treatment of moderately to severely active Crohn’s disease, moderately to severely active ulcerative colitis, moderate ...

Sales of J&J's blockbuster psoriasis treatment Stelara fell 14.7% to $2.35 billion in the fourth quarter. Analysts were expecting sales of $2.25 billion, according to LSEG data. Close copies of ...